Tony Rosenberg

He currently serves as Chief Executive Officer of TR Advisory Services GmbH, his own consultancy firm advising on business development, licensing, and mergers and acquisitions. Mr. Rosenberg also currently serves as chairman of the boards of directors of NUCLIDIUM AG, Oculis SA, and Cullinan Therapeutics Inc. Previously,, Mr. Rosenberg held the positions of Managing Director at MPM Capital, a venture capital firm (2015 until 2020), Head of M&A and Licensing at Novartis International (2013 to 2015), and Head of Business Development and Licensing at Novartis Pharma (2005 to 2012). Mr. Rosenberg also previously served on the boards of directors of SiO2 Material Science (until March 2023), Radius Health, Inc., TriNetX, Inc., iOmx Therapeutics AG, and Clinical Ink, Inc.